Molecular and Cellular Mechanisms of Cancers: Glioblastoma

Dear Colleagues,

Glioblastoma is the most aggressive brain tumor and one of the tumors with a worst clinical prognosis, with overall survival data of less than two years from diagnosis. Surgically, glioblastoma is difficult to be removed, due to its infiltrative pattern, which added to the fact that brain tumor stem cells may exist within it, make glioblastoma relapse very frequent. Radiotherapy and chemotherapy are also used against this tumor. Temozolomide is the chosen chemotherapy, especially for those patients who do not express MGMT, mostly due to MGMT promoter hypermethylation. But radiotherapy and temozolomide resistance appear as well. Molecular subtypes of glioblastoma have been established with the aim of assigning particular therapies to particular tumors. More research is needed, both at the genetic and epigenetic levels, in order to guarantee specific treatments to succeed.

We invite all scientists working on glioblastoma to participate in this special issue. Original research articles, reviews, or shorter perspective articles on all aspects related to the molecular and cellular mechanisms of glioblastoma biology and therapy are welcome. Articles with insights from a cell and molecular biological perspective are especially welcome. Relevant topics include, but are not limited to: genetic and epigenetic profiles, brain tumor stem cells, epithelial-to-mesenchymal transition, angiogenesis, migration and invasion, resistance to therapy, molecular and cellular heterogeneity, and any other topics related to the genetics and epigenetics of glioblastoma.

Prof. Javier S. Castresana
Dr. Bárbara Meléndez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.